Clinical Trials Logo

Filter by:
NCT ID: NCT03811288 Completed - Clinical trials for Diabetes Mellitus, Type 2

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes

CAPTURE-IO
Start date: December 10, 2018
Phase:
Study type: Observational

The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes patients across ten countries across the world. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than prescribed to them by their doctor. Participants' participation will be one day/one visit at their doctor. The study will last for about 6 months in total.

NCT ID: NCT03810586 Completed - Hypertension Clinical Trials

Comparing PPG-based Blood Pressure Measurement to the Gold Standard Manometer

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

Continuous blood pressure (BP) measurement is in use today with an ambulatory, sphygmomanometer-based, device. This device, also called BP Holter, gives essential data for the clinician, allowing better hypertension (HTN) diagnosis and treatment. Alongside, the device has some substantial limitations preventing its use as a longer term BP monitoring allowing better HTN control. A new method of continuous BP monitoring, based on photo plethysmography (PPG), has been invented to ease patients' use and increase their responsiveness. This study aims to check whether the new, PPG-based method, of BP measurement can be as good as the current, gold standard, sphygmomanometer-based device.

NCT ID: NCT03809429 Completed - Infertility, Female Clinical Trials

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

BEYOND
Start date: April 29, 2019
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.

NCT ID: NCT03808116 Completed - Breast Cancer Clinical Trials

Evaluation of the SmartBx System for Breast Biopsy

Start date: June 10, 2019
Phase: N/A
Study type: Interventional

Performance evaluation of a novel, semi-automated device and method for needle core biopsy download compared to standard methods in terms of: 3. Biopsy core length obtained (i.e. collecting all tissue fragments) 4. Biopsy core yield (i.e. percent of tissue loss during the pathologic processing)

NCT ID: NCT03807050 Completed - Clinical trials for Absorption; Chemicals

Safety and Pharmacokinetics of Phaffia Rhodozyma Astaxanthin

Start date: November 19, 2018
Phase: N/A
Study type: Interventional

Astaxanthin is a xanthophyll carotenoid, a naturally occurring lipid-soluble red pigment. Apart from its coloring ability it is also a strong antioxidative ingredient and contains health-promoting properties. Study aim is to monitor the safety and tolerability of AstaFerm™, an astaxanthin dietary supplement derived from the yeast Phaffia rhodozyma. Pharmacokinetics profile is tested in 12 healthy male adults who received a single dose of AstaFerm™ in a single-center, open-label, non-randomized, single-dose study. Subjects are admitted to the clinical research center on the evening before dosing. On the next morning, after overnight fast, pre-dosing plasma sampling is performed, then they receive a fat balanced breakfast followed by a single administration of AstaFerm™ capsules. The capsules contain 50 milligram astaxanthin derived from Phaffia rhodozyma. Following dosing, blood sampling is performed for 24 hours in-house (2, 4, 6, 8, 10, 12 and 24-hours post-dose) and ambulatory at 48, 72- and 168-hours post-dose. Blood for antioxidant activity assessment is also drawn.

NCT ID: NCT03805100 Completed - Clinical trials for Macular Degeneration

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

XPLORE
Start date: April 19, 2019
Phase: Phase 3
Study type: Interventional

The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).

NCT ID: NCT03800563 Completed - Clinical trials for Laser Assisted Liposuction

Laser Assisted Liposuction and Facial Autologous Fat Grafting With the LipoLife System

Start date: November 6, 2018
Phase: N/A
Study type: Interventional

Multi-center, prospective, open-label, single arm study. The study aims to evaluate the safety and efficacy of Laser Assisted Liposuction procedure performed with the LipoLife system. The study will include twenty (20) eligible subjects, that are willing to undergo abdominal or outer thighs laser-assisted liposuction. Five to twenty (5-20) subjects out of this study group should also be eligible for facial fat grafting. Follow up visits to evaluate study endpoints will take place at 1, 3 and 6 months after the surgery.

NCT ID: NCT03798964 Completed - Preterm Birth Clinical Trials

The Expression Heparanase in Term and Preterm Placentas

Start date: January 23, 2019
Phase:
Study type: Observational

Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM). This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) . The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.

NCT ID: NCT03796858 Completed - Clinical trials for Arthritis, Psoriatic

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy

COSMOS
Start date: March 22, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the reduction in signs and symptoms of joint disease.

NCT ID: NCT03796325 Completed - Depression Clinical Trials

Depressive State After Sleeve Gastrectomy

Start date: January 1, 2013
Phase:
Study type: Observational [Patient Registry]

Obesity is an epidemic disease that continues to increase causing morbidity and mortality to those who suffer. Obese patients suffer, frequently, from a depressive state, anger, and emotional disturbances. It cannot be recognized and depression causes obesity affecting eating habits or obesity causes depression based on physical, social and occupational limitations. Many times we see that obese patients are discriminated in every sense of daily life increasing their depressive state. The best treatment for obesity is bariatric surgery that causes a sufficient weight loss to correct sleep apnea, diabetes, hypertension, and many other co-morbidity. The study is based on elucidating the effect of sleeve gastrectomy in obese patients suffering from depression